IBOV 166,934.20 ▼ 0.10% IPSA 11,042.67 ▲ 0.39% IPC MEX 64,397.45 ▼ 0.66% MERVAL 2,947,349 ▼ 1.77% COLCAP 2,452.46 ▲ 0.84% BVL PERÚ 58,104.31 ▲ 0.40% USD/BRL5.22▼ 0.05% USD/MXN17.00▼ 0.17% USD/CLP914.45▼ 0.02% USD/COP3,131▼ 0.07% USD/PEN3.36▼ 0.23% USD/ARS1,488▼ 0.02% USD/UYU40.33— 0.00% USD/PYG5,984— 0.00% USD/BOB11.54— 0.00% USD/DOP58.31▼ 0.24% USD/CRC446.12— 0.00% USD/GTQ7.62— 0.00% USD/HNL26.79— 0.00% USD/NIO36.62— 0.00% USD/VES770.61▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.70— 0.00% EUR/BRL6.05▲ 0.12% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 166,934.20 ▼ 0.10% IPSA 11,042.67 ▲ 0.39% IPC MEX 64,397.45 ▼ 0.66% MERVAL 2,947,349 ▼ 1.77% COLCAP 2,452.46 ▲ 0.84% BVL PERÚ 58,104.31 ▲ 0.40% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Monday, August 17, 2026

Covid-19 Brazil

Deaths of elderly vaccinated with two doses rise by 73% in Brazil’s Rio de Janeiro

By · August 25, 2021 · 3 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

RIO DE JANEIRO, BRAZIL – Rio de Janeiro has seen deaths and hospitalizations of elderly administered the two coronavirus vaccine doses steadily increase. The numbers have been rising for about a month and a half and have alerted the authorities to the need to administer a third dose to this group.

Based on the preliminary analyses, the government reported that it “considers that a third dose would be recommended for the elderly.” (Photo internet reproduction)
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

Deaths in the over 60 age group increased from 64 to 111 when comparing the penultimate week of June and the second week of August (a 73% increase). Hospitalizations increased from 166 to 339 in the same period (104%), according to data from Rio de Janeiro’s Health Surveillance Subsecretariat.

Deaths and hospitalizations of people over 60 years of age for severe acute respiratory syndrome (SARS) were considered, on the dates they occurred. The data are from the federal Sivep-Gripe system and do not include the past two weeks to prevent delays in the records.

The two curves’ trajectories are similar: They show an increase from late March to mid-May (during the peak of the disease this year), but far below the total curve. Then they drop until the end of June, when they steadily rise again.

As a result, the proportion of elderly people with full vaccination coverage among severe cases has also been climbing. It increased from 7% of deaths in mid-May to 36% in August. With respect to hospitalizations, it rose from 12% to 31% in the same period.

The Francis Crick Institute, in collaboration with the British National Institute for Health Research, released a study on June 3 that showed that the Pfizer-BioNTech COVID-19 vaccine produced fewer neutralizing antibodies against COVID-19’s variants, particularly the Delta variant that is overwhelming Rio de Janeiro.

It found that only 25 percent of the people who received a single dose of the Pfizer vaccine had a quantifiable neutralizing antibody response against the Delta variant of Covid-19.  The situation is worse for older individuals who have weaker immune systems. The researchers found that older vaccine recipients generated even fewer antibodies.

Despite this, the State Health Secretariat points out that the “vaccines have effectively reduced deaths among the elderly, but people in this age group have more comorbidities and weaker health conditions due to the natural deterioration of the immune system caused by aging.”

The increase in fatal cases among fully immunized elderly people had already been noticed by the health secretariat. Now, the state’s officials are trying to understand if the main cause is, in fact, a reduction in immunity among the elderly, as they were the first targets of the vaccination campaign.

The ongoing study shows that, to date, the vaccine’s origin or manufacturer has not been relevant to the results. That is, deaths have increased the same among seniors administered the Coronavac, AstraZeneca, or Pfizer vaccines.

Based on the preliminary analyses, the state government reported that it “considers that a third dose would be recommended for the elderly.” However, it is waiting for the Ministry of Health’s decision: “For the measure to be implemented, the Ministry must supply the state with enough vaccines,” it said.

In other words, although the vaccines have failed to deliver on their original promises and can provide insufficient protection with one as well as two doses, now the third dose is supposed to change the situation.

Since this third dose means a further investment of billions, one may reasonably ask at this point to what extent the pharmaceutical industry has a hand in these decisions.

However, the Rio de Janeiro city hall has also taken a similar position. On Tuesday, August 24, Mayor Eduardo Paes reiterated that he “is very keen on providing the third dose for the elderly.” The municipality even announced that it will begin administering the vaccine in September, which also depends on deliveries from the federal government.

The rise in deaths among fully vaccinated elderly people in Rio de Janeiro is not reflected in an overall increase in this age group. The total number of deaths of people over 60 fell from 364 to 311 between the penultimate week of June and the second week of August (a 15% decrease).

The total number of elderly hospitalizations rose in the same period (from 852 to 1,090), although not in the same proportion. There was a 28% increase, therefore below the 104% recorded among those who have completed their vaccination schedule.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.